A new material developed at Cornell University could significantly improve the delivery and effectiveness of mRNA vaccines by ...

Replacing PEG with PCB in lipid nanoparticles led to potent mRNA vaccines that avoided unwanted immune responses.

This week, mRNA vaccines are set to face intense scrutiny from critics in Congress. Here's an explainer of how we know they ...

Inhalable nanovaccines offer needle-free, mucosal immunity against respiratory diseases like COVID-19, influenza, and TB. Explore delivery mechanisms, key technologies, and future breakthroughs.

Recent pre-clinical studies have shown that saRNA vaccines can offer longer-lasting immunity with smaller doses, and multiple ...

Moderna's avian flu vaccine contract canceled by HHS amid ongoing debates about mRNA technology safety and effectiveness.

Aphios has received a patent allowance for a single-dose, room temp-stable mRNA COVID-19 vaccine. No cold chain. No PEG. Just sustained protection.

The global lipid nanoparticles market is on the cusp of remarkable expansion, projected to grow at a CAGR of 14% through 2035, according to a recent industry analysis. Estimated to generate USD 1,144.

Over the past decade, lipid nanoparticles (LNPs) have become a cornerstone in the field of nucleic acid delivery, with applications extending from vaccines ...

In his recent paper, Jiang found that replacing PEG with PCB in lipid nanoparticle results in highly effective mRNA vaccines that do not adversely trigger the body’s immune system. Jiang is working ...